Cart
sales@molnova.com
AG18
CAS No. 118409-57-7
AG18( RG-50810 | RG-50858 | TX 825 | Tyrphostin 23 | Tyrphostin AG-18 )
Catalog No. M10624 CAS No. 118409-57-7
AG-18(RG-50810; Tyrphostin A23) inhibits EGFR with IC50 of 35 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 34 | In Stock |
|
| 10MG | 51 | In Stock |
|
| 25MG | 118 | In Stock |
|
| 50MG | 219 | In Stock |
|
| 100MG | 330 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAG18
-
NoteResearch use only, not for human use.
-
Brief DescriptionAG-18(RG-50810; Tyrphostin A23) inhibits EGFR with IC50 of 35 μM.
-
DescriptionAG-18(RG-50810; Tyrphostin A23) inhibits EGFR with IC50 of 35 μM.
-
In Vitro10 μM tyrphostin 23 causes significant inhibition of the cell proliferation caused by 1 nM and 1μM ghrelin. Tyrphostin 23 (T23) is a well-known inhibitor of protein tyrosine kinases and has been considered as potential anti-cancer drug. T23 is reported to acutely stimulate the glycolytic flux in primary cultured astrocytes. Tyrphostin 23 stimulates glycolytic flux in cultured astrocytes. Mitochondrial metabolism of brain astrocytes is accelerated by Tyrphostin 23 exposure.
-
In Vivo——
-
SynonymsRG-50810 | RG-50858 | TX 825 | Tyrphostin 23 | Tyrphostin AG-18
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number118409-57-7
-
Formula Weight186.17
-
Molecular FormulaC10H6N2O2
-
Purity>98% (HPLC)
-
SolubilityEthanol: 37 mg/mL (198.74 mM); DMSO: 37 mg/mL (198.74 mM)
-
SMILESN#C/C(C#N)=C/C1=CC=C(O)C(O)=C1
-
Chemical Name2-[(3,4-dihydroxyphenyl)methylene]-propanedinitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Gazit A, et al. J Med Chem, 1989, 32(10), 2344-2352.
molnova catalog
related products
-
Poziotinib
Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2/5.3 nM/23.5 nM for HER1/HER2/HER4.
-
Olmutinib (b)
Olmutinib (HM61713, BI-1482694) is a pontent and T790M-specific third-generation EGFR inhibitor for treatment of NSCLC.
-
DBPR112
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM for EGFRWT and 48 nM for EGFRL858R/T790M, capable of occupying the ATP-binding site and demonstrating significant antitumor efficacy.
